Potential value of tripartite motif-containing 59 as a biomarker for predicting the prognosis of patients with lung cancer: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
received:
21
07
2021
accepted:
22
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
1
9
2021
Statut:
ppublish
Résumé
In recent years, related studies have revealed that tripartite motif-containing 59 (TRIM59) is related to the prognosis of lung cancer. However, these results have not been proved by any evidence. Therefore, this study evaluated the relationship between TRIM59 and the prognosis of lung cancer by carrying out meta-analysis. In addition, we explored the mechanism and related pathways of TRIM59 in lung cancer through bioinformatics analysis. Comprehensive literature search was performed in China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang, Web of Science, PubMed, and EMBASE databases, and eligible studies were obtained based on the inclusion and exclusion criteria. The pooled hazard ratios and odds ratios were applied to assess the clinical value of TRIM59 expression for overall survival and clinicopathological features. Meanwhile, meta-analysis was conducted on the Stata 16.0. The mRNA expression level of TRIM59 in lung cancer was analyzed using Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) database. Gene Set Enrichment Analysis (GSEA) was used to predict the signaling pathways that TRIM59 might be involved in. The correlation between the expression level of TRIM59 in lung cancer and the abundance of immune cell invasion was analyzed by TIMER database. The survival analysis was verified by Kaplan-Meier Plotter database. The results of this meta-analysis would be submitted to peer-reviewed journals for publication. In this study, the application of meta-analysis and bioinformatics analysis will provide evidence support for the study on the prognosis and mechanism of TRIM59 in lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years, related studies have revealed that tripartite motif-containing 59 (TRIM59) is related to the prognosis of lung cancer. However, these results have not been proved by any evidence. Therefore, this study evaluated the relationship between TRIM59 and the prognosis of lung cancer by carrying out meta-analysis. In addition, we explored the mechanism and related pathways of TRIM59 in lung cancer through bioinformatics analysis.
METHODS
METHODS
Comprehensive literature search was performed in China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang, Web of Science, PubMed, and EMBASE databases, and eligible studies were obtained based on the inclusion and exclusion criteria. The pooled hazard ratios and odds ratios were applied to assess the clinical value of TRIM59 expression for overall survival and clinicopathological features. Meanwhile, meta-analysis was conducted on the Stata 16.0. The mRNA expression level of TRIM59 in lung cancer was analyzed using Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) database. Gene Set Enrichment Analysis (GSEA) was used to predict the signaling pathways that TRIM59 might be involved in. The correlation between the expression level of TRIM59 in lung cancer and the abundance of immune cell invasion was analyzed by TIMER database. The survival analysis was verified by Kaplan-Meier Plotter database.
RESULTS
RESULTS
The results of this meta-analysis would be submitted to peer-reviewed journals for publication.
CONCLUSION
CONCLUSIONS
In this study, the application of meta-analysis and bioinformatics analysis will provide evidence support for the study on the prognosis and mechanism of TRIM59 in lung cancer.
Identifiants
pubmed: 34397900
doi: 10.1097/MD.0000000000026868
pii: 00005792-202108130-00034
pmc: PMC8360424
doi:
Substances chimiques
Biomarkers, Tumor
0
Intracellular Signaling Peptides and Proteins
0
TRIM59 protein, human
0
Tripartite Motif Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26868Subventions
Organisme : scientific research project of wuxi health and family planning commission
ID : MS201718
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Cai Z, Liu Q. Understanding the Global cancer statistics 2018: implications for cancer control. Sci China Life Sci 2021;64:1017–20.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol 2020;38:753–66.
Sun A, Durocher-Allen LD, Ellis PM, et al. Guideline for the initial management of small cell lung cancer (limited and extensive stage) and the role of thoracic radiotherapy and first-line chemotherapy. Clin Oncol 2018;30:658–66.
Han Q, Cheng P, Yang H, Liang H, Lin F. Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression. J Cell Physiol 2019;234:22321–30.
Valiyeva F, Jiang F, Elmaadawi A, et al. Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models. Mol Cancer Ther 2011;10:1229–40.
Zhang P, Zhang H, Wang Y, Zhang P, Qi Y. Tripartite motif-containing protein 59 (TRIM59) promotes epithelial ovarian cancer progression via the focal adhesion kinase (FAK)/AKT/matrix metalloproteinase (MMP) pathway. Med Sci Monit 2019;25:3366–73.
Wang M, Chao C, Luo G, et al. Prognostic significance of TRIM59 for cancer patient survival: a systematic review and meta-analysis. Medicine 2019;98:e18024.
Wang Y, Zhou Z, Wang X, et al. TRIM59 is a novel marker of poor prognosis and promotes malignant progression of ovarian cancer by inducing annexin A2 expression. Int J Biol Sci 2018;14:2073–82.
Aierken G, Seyiti A, Alifu M, Kuerban G. Knockdown of tripartite-59 (TRIM59) inhibits cellular proliferation and migration in human cervical cancer cells. Oncol Res 2017;25:381–8.
Zhou Z, Ji Z, Wang Y, et al. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology 2014;147:1043–54.
Tan P, Ye Y, He L, et al. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10. PLoS Biol 2018;16:e3000051.
Shen H, Zhang J, Zhang Y, et al. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Gene 2019;698:50–60.
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed) 2015;350:g7647.
Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337–51.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:01–16.
Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review. VASA Zeitschrift fur Gefasskrankheiten 2020;49:141–6.
Lewis SJ, Zammit S, Gunnell D, Smith GD. Bias in meta-analysis detected by a simple, graphical test. BMJ Clin Res 1997;315:629–34.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
Li R, Weng L, Liu B, et al. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. J Cell Biochem 2020;121:1986–97.
Geng B, Liang M, Qin L, et al. An TRIM59-CDK6 axis regulates growth and metastasis of lung cancer. J Cell Mol Med 2019;23:1458–69.
Kondo T, Watanabe M, Hatakeyama S. TRIM59 interacts with ECSIT and negatively regulates NF-κB and IRF-3/7-mediated signal pathways. Biochem Biophys Res Commun 2012;422:501–7.
Sun Y, Ji B, Feng Y, et al. TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway. Oncology reports 2017;38:43–52.
Liang M, Chen X, Wang L, et al. Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression. J Exp Clin Cancer Res 2020;39:176.
Lou M, Gao Z, Zhu T, et al. TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC. Oncol Lett 2020;19:1400–8.
Tian H, Zhang D, Xu R, et al. Expression of TRIM59 in non-small cell lung cancer and its correlation with prognosis. Zhongguo fei ai za zhi 2020;23:21–8.
Li C, Yang X, Qian H, et al. TRIM59's expressions, clinical significance and correlation with c-myc, CDC25A in non-small cell lung cancer. Acta Univ Med Anhui 2020;2:287–91.
Tang N, Bao Z, Liu N. Expression and clinical significance of lncRNA UFC1 and TRIM59 in non-small-cell lung cancer. Shandong Med J 2021;61:24–7.